loading
Schlusskurs vom Vortag:
$11.06
Offen:
$10.97
24-Stunden-Volumen:
405.99K
Relative Volume:
2.07
Marktkapitalisierung:
$597.61M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-5.83%
1M Leistung:
-25.76%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
Value
$10.97
$11.84
1-Wochen-Bereich:
Value
$10.90
$12.24
52-Wochen-Spanne:
Value
$10.82
$16.50

Eikon Therapeutics Inc Stock (EIKN) Company Profile

Name
Firmenname
Eikon Therapeutics Inc
Name
Telefon
-
Name
Adresse
-
Name
Mitarbeiter
0
Name
Twitter
Name
Nächster Verdiensttermin
Name
Neueste SEC-Einreichungen
Name
EIKN's Discussions on Twitter

Compare EIKN vs VRTX, REGN, ARGX, ALNY, INSM

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
EIKN icon
EIKN
Eikon Therapeutics Inc
11.07 597.07M 0 0 0 0.00
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
457.62 113.96B 12.07B 3.95B 3.19B 15.33
REGN icon
REGN
Regeneron Pharmaceuticals Inc
749.61 78.41B 14.34B 4.50B 3.77B 41.56
ARGX icon
ARGX
Argen X Se Adr
698.92 42.05B 4.16B 1.29B 734.26M 19.58
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
327.18 40.85B 3.71B 313.75M 465.38M 2.2571
INSM icon
INSM
Insmed Inc
148.46 29.99B 606.42M -1.28B -997.58M -6.403

Eikon Therapeutics Inc Stock (EIKN) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2026-03-02 Eingeleitet BofA Securities Buy
2026-03-02 Eingeleitet Cantor Fitzgerald Overweight
2026-03-02 Eingeleitet JP Morgan Overweight
2026-03-02 Eingeleitet Mizuho Outperform
2026-03-02 Eingeleitet Morgan Stanley Overweight
2026-02-26 Eingeleitet Wedbush Underperform
Alle ansehen

Eikon Therapeutics Inc Aktie (EIKN) Neueste Nachrichten

pulisher
Mar 22, 2026

Eikon Therapeutics, Inc.(NasdaqGS: EIKN) added to S&P TMI Index - marketscreener.com

Mar 22, 2026
pulisher
Mar 10, 2026

Eikon Therapeutics (EIKN) Stock Analysis Report | Financials & Insights - Benzinga Japan

Mar 10, 2026
pulisher
Mar 04, 2026

Eikon Therapeutics (EIKN) grants 25,873-share stock option award to director - Stock Titan

Mar 04, 2026
pulisher
Mar 04, 2026

Eikon Therapeutics (EIKN) grants director Kenneth Frazier 25,873 options - Stock Titan

Mar 04, 2026
pulisher
Mar 04, 2026

Large stock option grant to Eikon Therapeutics (EIKN) director and officer - Stock Titan

Mar 04, 2026
pulisher
Mar 04, 2026

Eikon Therapeutics (EIKN) COO awarded 87,157-share stock option grant - Stock Titan

Mar 04, 2026
pulisher
Mar 02, 2026

Eikon Therapeutics Shares Jump 6% as Brokerages Initiate Coverage By Investing.com - Investing.com Canada

Mar 02, 2026
pulisher
Mar 02, 2026

Eikon Therapeutics Shares Jump 6% as Brokerages Initiate Coverage - Investing.com UK

Mar 02, 2026
pulisher
Mar 02, 2026

BofA initiates Eikon Therapeutics stock with buy rating on platform potential - Investing.com Australia

Mar 02, 2026
pulisher
Mar 02, 2026

BofA Securities Initiates Eikon Therapeutics at Buy With $34 Price Target - marketscreener.com

Mar 02, 2026
pulisher
Mar 02, 2026

Cantor Fitzgerald Initiates Eikon Therapeutics at Overweight - marketscreener.com

Mar 02, 2026
pulisher
Mar 02, 2026

This NextTrip Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga

Mar 02, 2026
pulisher
Mar 02, 2026

Mizuho Initiates Eikon Therapeutics at Outperform With $26 Price Target - marketscreener.com

Mar 02, 2026
pulisher
Mar 02, 2026

BofA initiates Eikon Therapeutics stock with buy rating on platform potential By Investing.com - Investing.com South Africa

Mar 02, 2026
pulisher
Mar 02, 2026

Morgan Stanley Initiates Eikon Therapeutics at Overweight With $32 Price Target - marketscreener.com

Mar 02, 2026
pulisher
Mar 02, 2026

Mizuho initiates Eikon Therapeutics stock coverage with outperform - Investing.com Nigeria

Mar 02, 2026
pulisher
Mar 02, 2026

JPMorgan initiates Eikon Therapeutics stock at Overweight By Investing.com - Investing.com Nigeria

Mar 02, 2026
pulisher
Mar 02, 2026

Morgan Stanley initiates Eikon Therapeutics stock coverage at overweight By Investing.com - Investing.com South Africa

Mar 02, 2026
pulisher
Mar 02, 2026

Morgan Stanley initiates Eikon Therapeutics stock coverage at overweight - Investing.com India

Mar 02, 2026
pulisher
Mar 02, 2026

JPMorgan initiates Eikon Therapeutics stock at Overweight - Investing.com UK

Mar 02, 2026
pulisher
Mar 01, 2026

Bank of America Global Research recently announced the official initiation of research coverage on biotechnology company Eikon Therapeutics (stock code: EIKN), and assigned an initial "Buy" rating. - Bitget

Mar 01, 2026
pulisher
Feb 27, 2026

Bay Area life sciences firms raise $6.1B as three companies go public - The Business Journals

Feb 27, 2026
pulisher
Feb 27, 2026

Eikon Therapeutics, Inc.Common Stock (NQ: EIKN - The Chronicle-Journal

Feb 27, 2026
pulisher
Feb 27, 2026

Eikon Therapeutics, Inc.: Dividend historical data and projections - marketscreener.com

Feb 27, 2026
pulisher
Feb 27, 2026

Eikon Therapeutics, Inc.: Target Price Consensus and Analysts Recommendations | EIKN | US2825641036 - marketscreener.com

Feb 27, 2026
pulisher
Feb 26, 2026

Eikon Therapeutics stock drops after Wedbush downgrade By Investing.com - Investing.com Australia

Feb 26, 2026
pulisher
Feb 26, 2026

Eikon Therapeutics stock drops after Wedbush downgrade - Investing.com South Africa

Feb 26, 2026
pulisher
Feb 26, 2026

Wedbush initiates Eikon Therapeutics stock with underperform rating - Investing.com South Africa

Feb 26, 2026
pulisher
Feb 26, 2026

Wedbush initiates Eikon Therapeutics stock with underperform rating By Investing.com - Investing.com Australia

Feb 26, 2026
pulisher
Feb 24, 2026

User - The Chronicle-Journal

Feb 24, 2026
pulisher
Feb 20, 2026

EIKN Should I Buy - Intellectia AI

Feb 20, 2026
pulisher
Feb 18, 2026

ADIA and Platinum Falcon disclose 2.82M EIKN shares (ADIA affiliate ownership) - Stock Titan

Feb 18, 2026
pulisher
Feb 12, 2026

EIKN SEC FilingsEikon Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan

Feb 12, 2026
pulisher
Feb 11, 2026

What is the current Price Target and Forecast for Eikon Therapeutics, Inc. (EIKN) - Zacks Investment Research

Feb 11, 2026
pulisher
Feb 10, 2026

Insider Stock Purchases: February 10, 2026 - Quiver Quantitative

Feb 10, 2026
pulisher
Feb 09, 2026

Eikon Therapeutics Prices $381 Million Initial Public Offering - Global Legal Chronicle

Feb 09, 2026
pulisher
Feb 09, 2026

Wall Street Braces For IPO Boom: Goldman Says 2026 Listings Could Hit $160 Billion As Tech, AI Lead - Benzinga

Feb 09, 2026
pulisher
Feb 08, 2026

Merck veteran-led Eikon seeks $908M valuation in US IPO - MSN

Feb 08, 2026
pulisher
Feb 07, 2026

Eikon Therapeutics completes IPO and updates governance documents - The Globe and Mail

Feb 07, 2026
pulisher
Feb 06, 2026

Eikon, Agomab raise $350M total in IPOs, sink in aftermarket: Public Equity Report - biocentury.com

Feb 06, 2026
pulisher
Feb 06, 2026

Eikon Therapeutics, Inc (EIKN) Stock Price Today & Analysis - Gotrade

Feb 06, 2026
pulisher
Feb 06, 2026

Finance Watch: Four IPOs In One Week - Citeline News & Insights

Feb 06, 2026
pulisher
Feb 06, 2026

Merck veteran Perlmutter-led Eikon ‍Therapeutics valued at $860 million in Nasdaq debut - WTAQ

Feb 06, 2026
pulisher
Feb 06, 2026

It was supposed to be the biggest week for IPOs in years. But a 'selective' market didn't cooperate - The Business Journals

Feb 06, 2026
pulisher
Feb 05, 2026

Eikon Therapeutics, Late-Stage Clinical Oncology Drug Developer, Files for Nasdaq IPO - TradingView

Feb 05, 2026
pulisher
Feb 05, 2026

Eikon Therapeutics valued at $860 million in Nasdaq debut - marketscreener.com

Feb 05, 2026

Finanzdaten der Eikon Therapeutics Inc-Aktie (EIKN)

Es liegen keine Finanzdaten für Eikon Therapeutics Inc (EIKN) vor. Überprüfen Sie andere Aktien für weitere Informationen.

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$27.48
price up icon 2.14%
$46.80
price up icon 2.61%
$53.28
price up icon 3.92%
$88.98
price up icon 2.51%
ONC ONC
$283.31
price up icon 2.47%
$148.31
price up icon 6.43%
Kapitalisierung:     |  Volumen (24h):